Provided by Tiger Trade Technology Pte. Ltd.

Assembly Biosciences

35.06
+1.434.25%
Volume:240.30K
Turnover:8.27M
Market Cap:713.84M
PE:-13.66K
High:35.30
Open:34.12
Low:33.43
Close:33.63
52wk High:39.71
52wk Low:20.23
Shares:20.36M
Float Shares:9.17M
Volume Ratio:0.88
T/O Rate:2.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0026
EPS(LYR):-0.5461
ROE:-0.03%
ROA:-2.67%
PB:2.34
PE(LYR):-64.20

Loading ...

H.C. Wainwright Reaffirms Their Buy Rating on Assembly Biosciences (ASMB)

TIPRANKS
·
Jun 04

Assembly Biosciences Announces Upcoming Investor Conference Presentations

GlobeNewswire
·
May 29

Analysts Offer Insights on Healthcare Companies: Assembly Biosciences (ASMB), Apogee Therapeutics (APGE) and Align Tech (ALGN)

TIPRANKS
·
May 28

Assembly Biosciences Price Target Maintained With a $43.00/Share by Guggenheim

Dow Jones
·
May 28

Guggenheim Sticks to Their Buy Rating for Assembly Biosciences (ASMB)

TIPRANKS
·
May 28

Assembly Bio publishes corporate presentation on clinical-stage antiviral and liver disease pipeline, Gilead partnership

Reuters
·
May 27

Assembly Biosciences Closes Securities Offering

MT Newswires Live
·
May 27

Assembly Biosciences Completes Significant Equity Offering Financing

TIPRANKS
·
May 27

Assembly Biosciences closes USD 115 million follow-on stock, pre-funded warrant offering at USD 26.5 per share

Reuters
·
May 27

Press Release: Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Dow Jones
·
May 27

Assembly Biosciences Prices $100 Million Offering

MT Newswires Live
·
May 22

Assembly Bio prices USD 100 million follow-on offering at USD 26.5 per share

Reuters
·
May 22

Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

THOMSON REUTERS
·
May 22

Assembly Biosciences Inc - Prices 3.4 Mln Shares at $26.50 and 415,000 Pre-Funded Warrants at $26.499 Each

THOMSON REUTERS
·
May 22

Assembly Biosciences Inc: Plans to Initiate a Phase 2 Clinical Study of Abi-6250 in Hdv in Q4 of 2026

THOMSON REUTERS
·
May 22

Assembly Biosciences Announces Expansion of Abi-6250 Clinical Development Into Cholestatic Liver Diseases

THOMSON REUTERS
·
May 22

Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases

GlobeNewswire
·
May 22

Analyst Reiterates Buy on Assembly Biosciences, Maintains $50 Price Target Amid Pipeline Progress and 2028 Cash Runway

TIPRANKS
·
May 14

Assembly Bio to present topline Phase 1a data for HDV entry inhibitor ABI-6250 at EASL 2026

Reuters
·
May 13

Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference

GlobeNewswire
·
May 11